Lumen Hopes FiberNet Will Capture Attention Of Potential Acquirers
This article was originally published in The Gray Sheet
Executive Summary
Lumen Biomedical is counting on the adaptable material and three-dimensional design of its early-stage FiberNet embolic protection device to capture the attention of potential purchasers
You may also be interested in...
Lumen Biomedical Xtract clot buster
Plymouth, Minn.-based firm announces 510(k) clearance of its aspiration catheter for removal of thrombi and soft emboli from vessels throughout the body on July 5. Xtract, which is the firm's first product to receive FDA marketing go-ahead, will be a component of the firm's FiberNet embolic protection system, currently in clinical trials...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.